Endocrine ‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma

ConclusionsOur cohort demonstrated an increased incidence of hypophysitis with anti ‐PD1/anti‐PDL1 in contrast to the rarity of primary thyroid dysfunction with anti‐CTLA4 treatment. These results could be attributed to genetic/ethnic differences. Sequential treatment is, for the first time to our knowledge, reported to increase the risk of developing hypophysitis to a level as high as that of combination therapy.

Source: Cancer Medicine - September 12, 2019 Category: Cancer & Oncology Authors: Eva Kassi, Anna Angelousi, Nikolaos Asonitis, Panagiotis Diamantopoulos, Amalia Anastasopoulou, George Papaxoinis, Michalis Kokkinos, Ilias Giovanopoulos, Georgios Kyriakakis, Fotini Petychaki, Akrivi Savelli, Olga Benopoulou, Helen Gogas Tags: ORIGINAL RESEARCH Source Type: research